News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ophthotech Corporation Enrolls First Patient in Phase 3 Clinical Trial of Fovista™ Anti-PDGF Therapy in Combination With Anti-VEGF Therapy for Wet AMD


8/30/2013 9:59:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation today announced the initiation of patient enrollment in a pivotal Phase 3 clinical trial of its lead compound FovistaTM, an anti-platelet-derived growth factor (PDGF), which is being studied in combination with anti-VEGF therapy for the treatment of newly diagnosed patients with neovascular age-related macular degeneration (wet AMD). The announcement marks the treatment of the first patient in the global Fovista Phase 3 clinical program, which consists of three clinical trials evaluating the safety and efficacy of the Fovista/anti-VEGF combination. The three trials are expected to enroll a total of approximately 1,866 patients at up to approximately 225 centers internationally.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES